Caveolin-1 upregulation contributes to c-Myc-induced high-grade prostatic intraepithelial neoplasia and prostate cancer

Molecular Cancer Research

Volumn 10, Issue 2, 2012, Pages 218-229

  Yang, Guang ^a   Goltsov, Alexei A ^a   Ren, Chengzhen ^a   Kurosaka, Shinji ^a   Edamura, Kohei ^a   Logothetis, Richard ^a   DeMayo, Francesco J ^b   Troncoso, Patricia ^a   Blando, Jorge ^a,c   DiGiovanni, John ^a,c   Thompson, Timothy C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; CYCLINE; MESSENGER RNA; PROTEIN KINASE B; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GRADING; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MALE; METAPLASIA; MOUSE; NONHUMAN; ONCOGENE C MYC; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TRANSGENE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; CAVEOLIN 1; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, TRANSGENIC; NEOPLASM STAGING; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857224992     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0451     Document Type: Article

References (38)

1. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74. (Pubitemid 24037911)
2. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4. (Pubitemid 23175983)
3. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51. (Pubitemid 27208886)
4. Harder T, Simons K. Caveolae, DIGs, and the dynamics of sphingo-lipid- cholesterol microdomains. Curr Opin Cell Biol 1997;9:534-42.
5. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005;288:C494-506. (Pubitemid 40229478)
6. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998;4:1873-80. (Pubitemid 28369170)
7. Watanabe M, Yang G, Cao G, Tahir SA, Naruishi K, Tabata K, et al. Functional analysis of secreted caveolin-1 in mouse models of prostate cancer progression. Mol Cancer Res 2009;7:1446-55.
8. Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem 2005;280:25134-45. (Pubitemid 40934606)
9. Nasu Y, Timme TL, Yang G,Bangma CH, Li L, Ren C, et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 1998;4: 1062-4. (Pubitemid 28417340)
10. Yang G, Truong LD, Wheeler TM, Thompson TC. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 1999;59:5719-23.
11. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003;23: 9389-404. (Pubitemid 37499824)
12. Li L, Ren C, Yang G, Goltsov AA, Tabata K, Thompson TC. Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells. Mol Cancer Res 2009;7:1781-91.
13. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, et al. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 2008;68:731-9. (Pubitemid 351206749)
14. Di Vizio D, Sotgia F, Williams TM, Hassan GS, Capozza F, Frank PG, et al. Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression. Cancer Biol Ther 2007;6:1263-8. (Pubitemid 351590381)
15. Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 2001;276:13442-51.
16. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
17. Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol 2008;21:1156-67.
18. Williams K, Fernandez S, Stien X, Ishii K, Love HD, Lau YF, et al. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate 2005;63:369-84. (Pubitemid 40664349)
19. Zhang X, Lee C, Ng PY, Rubin M, Shabsigh A, Buttyan R. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate 2000;43:278-85. (Pubitemid 30367963)
20. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-38. (Pubitemid 37163836)
21. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56:917-30. (Pubitemid 19091004)
22. Wu D, Terrian DM. Regulation of caveolin-1 expression and secretion by a protein kinase cepsilon signaling pathway in human prostate cancer cells. J Biol Chem 2002;277:40449-55. (Pubitemid 35215621)
23. Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, et al. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 2000;19:3256-65. (Pubitemid 30487412)
24. Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 2005;103:1186-94. (Pubitemid 40328089)
25. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000;141:4698-710. (Pubitemid 32055150)
26. Ma ZQ, Chua SS, DeMayo FJ, Tsai SY. Induction of mammary gland hyperplasia in transgenic mice over-expressing human Cdc25B. Oncogene 1999;18:4564-76. (Pubitemid 29405888)
27. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-305. (Pubitemid 38339483)
28. Tahir SA, Frolov A, Hayes TG, Mims MP, Miles BJ, Lerner SP, et al. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res 2006;12:4872-5. (Pubitemid 44338573)
29. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11. (Pubitemid 29018404)
30. Evan G, Littlewood T. A matter of life and cell death. Science 1998;281:1317-22. (Pubitemid 28406818)
31. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, et al. Function of the c-Myc oncogenic transcription factor. Exp Cell Res 1999;253:63-77.
32. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997;385:544-8. (Pubitemid 27074674)
33. Rohn JL, Hueber AO, McCarthy NJ, Lyon D, Navarro P, Burgering BM, et al. The opposing roles of the Akt and c-Myc signalling pathways in survival from CD95-mediated apoptosis. Oncogene 1998;17:2811-8. (Pubitemid 29010051)
34. Ramljak D, Coticchia CM, Nishanian TG, Saji M, Ringel MD, Conzen SD, et al. Epidermal growth factor inhibition of c-Myc-mediated apoptosis through Akt and Erk involves Bcl-xL upregulation in mammary epithelial cells. Exp Cell Res 2003;287:397-410. (Pubitemid 37323851)
35. Bist A, Fielding PE, Fielding CJ. Two sterol regulatory element-like sequences mediate up-regulation of caveolin gene transcription in response to low density lipoprotein free cholesterol. Proc Natl Acad Sci U S A 1997;94:10693-8. (Pubitemid 27430796)
36. Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002;16:2530-43.
37. Mezquita P, Parghi SS, Brandvold KA, Ruddell A. Myc regulates VEGF production in B cells by stimulating initiation of VEGF mRNA translation. Oncogene 2005;24:889-901. (Pubitemid 40216097)
38. Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, Chung DH. Nmyc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene 2008;27:3999-4007. (Pubitemid 351913633)